Bromfenac free base

• CAT Number: I023717
• CAS Number: 91714-94-2
• Molecular Formula: C15H12BrNO3
• Molecular Weight: 334.17
• Purity: 98%
• Synonyms: Bromfenac Free Base; AHR10282; AHR-10282; AHR 10282
• Target: COX
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-[2-amino-3-(4-bromobenzoyl)phenyl]acetic acid
• InChI: InChI=1S/C15H12BrNO3/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19/h1-7H,8,17H2,(H,18,19)
• InChIKey: ZBPLOVFIXSTCRZ-UHFFFAOYSA-N
• SMILES: C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O

Bromfenac free base（Cat No.:I023717）is a nonsteroidal anti-inflammatory drug (NSAID) used primarily in ophthalmology to reduce inflammation and pain following eye surgery, such as cataract surgery. It works by inhibiting cyclooxygenase (COX) enzymes, particularly COX-2, reducing the production of prostaglandins that contribute to inflammation and discomfort. As the free base form, bromfenac is more readily available for formulation into eye drops, providing local action with minimal systemic absorption. Its effectiveness in managing post-surgical inflammation and reducing ocular pain makes it a valuable therapeutic option in eye care.

Reference

1: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Bromfenac. 2018 Dec 3. PMID: 30000016.
2: Wentz SM, Price F, Harris A, Siesky B, Ciulla T. Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery. Expert Opin Pharmacother. 2019 Oct;20(14):1703-1709. doi: 10.1080/14656566.2019.1645834. Epub 2019 Jul 25. PMID: 31343372.
3: Chen K, Lai K, Zhang X, Qin Z, Fu Q, Luo C, Jin X, Hu J, Liu S, Yao K. Bromfenac Inhibits TGF-β1-Induced Fibrotic Effects in Human Pterygium and Conjunctival Fibroblasts. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1156-1164. doi: 10.1167/iovs.18-24743. PMID: 30908581.
4: Aguilar Sierra MC, Alvarado-Villacorta R, Pastrana CP. Topical Bromfenac Sodium in Femtosecond Laser-Assisted Cataract Surgery. J Curr Ophthalmol. 2020 Mar 23;32(1):32-37. doi: 10.1016/j.joco.2019.07.007. PMID: 32510011; PMCID: PMC7265276.
5: Hoy SM. Bromfenac Ophthalmic Solution 0.07%: A Review of Its Use After Cataract Surgery. Clin Drug Investig. 2015 Aug;35(8):525-9. doi: 10.1007/s40261-015-0309-3. PMID: 26177719.
6: Sheppard JD. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clin Ophthalmol. 2016 Oct 25;10:2099-2111. doi: 10.2147/OPTH.S86971. PMID: 27822006; PMCID: PMC5087782.
7: Silverstein SM. Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose. Ophthalmol Ther. 2019 Dec;8(4):577-587. doi: 10.1007/s40123-019-00215-y. Epub 2019 Sep 24. PMID: 31552543; PMCID: PMC6858409.
8: Song SH, Baek SK, Lee MW, Lee YH. Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes. Korean J Ophthalmol. 2020 Feb;34(1):46-55. doi: 10.3341/kjo.2019.0044. PMID: 32037749; PMCID: PMC7010466.
9: Schechter BA. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019 Aug 1;13:1439-1460. doi: 10.2147/OPTH.S208700. PMID: 31534309; PMCID: PMC6682171.
10: Yadav AS, Shah NR, Carlson TJ, Driscoll JP. Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac †. Chem Res Toxicol. 2020 Jan 21;33(1):249-257. doi: 10.1021/acs.chemrestox.9b00268. Epub 2019 Dec 23. PMID: 31815452.